Biocon gets DCGI nod to use Itolizumab in moderate to severe Covid-19 patients
Posted by
www.biotecnika.org
Biocon said the approval is based on the results from the successful
conclusion of a randomized, controlled clinical trial at multiple
hospitals in Mumbai and New Delhi. The drug inhibits the production of
pro-inflammatory cytokines, proteins released by cells. Cytokine storm
is a complication of Covid-19.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/biocon-gets-dcgi-nod-to-use-itolizumab-in-moderate-to-severe-covid-19-patients/articleshow/76909667.cms
Subscribe to:
Post Comments (Atom)
Post a Comment